These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20413708)

  • 1. How proteins adapt: lessons from directed evolution.
    Arnold FH
    Cold Spring Harb Symp Quant Biol; 2009; 74():41-6. PubMed ID: 20413708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the activity of cytochrome P450 BM-3 catalyzing indole hydroxylation by directed evolution.
    Pengpai Z; Sheng H; Lehe M; Yinlin L; Zhihua J; Guixiang H
    Appl Biochem Biotechnol; 2013 Sep; 171(1):93-103. PubMed ID: 23817788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A highly active single-mutation variant of P450BM3 (CYP102A1).
    Whitehouse CJ; Bell SG; Yang W; Yorke JA; Blanford CF; Strong AJ; Morse EJ; Bartlam M; Rao Z; Wong LL
    Chembiochem; 2009 Jul; 10(10):1654-6. PubMed ID: 19492389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altering the regioselectivity of the subterminal fatty acid hydroxylase P450 BM-3 towards gamma- and delta-positions.
    Dietrich M; Do TA; Schmid RD; Pleiss J; Urlacher VB
    J Biotechnol; 2009 Jan; 139(1):115-7. PubMed ID: 18984016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxylation of non-substituted polycyclic aromatic hydrocarbons by cytochrome P450 BM3 engineered by directed evolution.
    Sideri A; Goyal A; Di Nardo G; Tsotsou GE; Gilardi G
    J Inorg Biochem; 2013 Mar; 120():1-7. PubMed ID: 23262457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein engineering of the cytochrome P450 monooxygenase from Bacillus megaterium.
    Urlacher VB; Schmid RD
    Methods Enzymol; 2004; 388():208-24. PubMed ID: 15289074
    [No Abstract]   [Full Text] [Related]  

  • 7. Rational design of a minimal and highly enriched CYP102A1 mutant library with improved regio-, stereo- and chemoselectivity.
    Seifert A; Vomund S; Grohmann K; Kriening S; Urlacher VB; Laschat S; Pleiss J
    Chembiochem; 2009 Mar; 10(5):853-61. PubMed ID: 19222039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolved CYP102A1 (P450BM3) variants oxidise a range of non-natural substrates and offer new selectivity options.
    Whitehouse CJ; Bell SG; Tufton HG; Kenny RJ; Ogilvie LC; Wong LL
    Chem Commun (Camb); 2008 Feb; (8):966-8. PubMed ID: 18283351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel semi-biosynthetic route for artemisinin production using engineered substrate-promiscuous P450(BM3).
    Dietrich JA; Yoshikuni Y; Fisher KJ; Woolard FX; Ockey D; McPhee DJ; Renninger NS; Chang MC; Baker D; Keasling JD
    ACS Chem Biol; 2009 Apr; 4(4):261-7. PubMed ID: 19271725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Missense meanderings in sequence space: a biophysical view of protein evolution.
    DePristo MA; Weinreich DM; Hartl DL
    Nat Rev Genet; 2005 Sep; 6(9):678-87. PubMed ID: 16074985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Directed evolution of cytochrome P450 for sterol epoxidation.
    Jiang D; Tu R; Bai P; Wang Q
    Biotechnol Lett; 2013 Oct; 35(10):1663-8. PubMed ID: 23794050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regioselectivity-driven evolution of CYP102D1 for improved synthesis of 3'-ortho-dihydroxyisoflavone.
    Choi KY; Yang YH; Kim BG
    Enzyme Microb Technol; 2015 Apr; 71():20-7. PubMed ID: 25765306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered alkane-hydroxylating cytochrome P450(BM3) exhibiting nativelike catalytic properties.
    Fasan R; Chen MM; Crook NC; Arnold FH
    Angew Chem Int Ed Engl; 2007; 46(44):8414-8. PubMed ID: 17886313
    [No Abstract]   [Full Text] [Related]  

  • 14. Protein and electrode engineering for the covalent immobilization of P450 BMP on gold.
    Ferrero VE; Andolfi L; Di Nardo G; Sadeghi SJ; Fantuzzi A; Cannistraro S; Gilardi G
    Anal Chem; 2008 Nov; 80(22):8438-46. PubMed ID: 18947200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding the applicability of cytochrome P450s and other haemoproteins.
    Ariyasu S; Stanfield JK; Aiba Y; Shoji O
    Curr Opin Chem Biol; 2020 Dec; 59():155-163. PubMed ID: 32781431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning, expression and characterisation of CYP102A7, a self-sufficient P450 monooxygenase from Bacillus licheniformis.
    Dietrich M; Eiben S; Asta C; Do TA; Pleiss J; Urlacher VB
    Appl Microbiol Biotechnol; 2008 Jul; 79(6):931-40. PubMed ID: 18483737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory evolution of P450 BM3 for mediated electron transfer yielding an activity-improved and reductase-independent variant.
    Nazor J; Dannenmann S; Adjei RO; Fordjour YB; Ghampson IT; Blanusa M; Roccatano D; Schwaneberg U
    Protein Eng Des Sel; 2008 Jan; 21(1):29-35. PubMed ID: 18093991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flavin-containing heme enzymes.
    Mowat CG; Gazur B; Campbell LP; Chapman SK
    Arch Biochem Biophys; 2010 Jan; 493(1):37-52. PubMed ID: 19850002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating a screen and analysis of mutant libraries.
    Salazar O; Sun L
    Methods Mol Biol; 2003; 230():85-97. PubMed ID: 12824571
    [No Abstract]   [Full Text] [Related]  

  • 20. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
    Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
    J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.